Please sign in to follow a disease.
Could A2 milk be the answer to tummy troubles?
NCT ID NCT06252636
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether A2 milk causes fewer digestive issues like bloating, gas, and stomach pain compared to regular milk. About 40 adults who often feel discomfort after drinking milk will try both types of milk over 8 weeks. The goal is to see if A2 milk is a gentler option for sensitive stomachs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
40 people
The number who actually took part.
- Started
-
Apr 2023
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Between 20 to 70 years of age 2. Participants who are experiencing digestive symptoms (bloating, gas, heaviness, abdominal pain, gurgling stomach, belching, bowel urgency) following milk consumption on Visit 1 with each score on the digestive discomfort symptom survey being 2 points or less. (Individuals who have indicated 0 in all symptoms or 3 in at least one symptom will be excluded.) 3. Those who have agreed to participate and given written consent through the Informed Consent Form prior to the study Exclusion Criteria: 1. Currently undergoing treatment for severe cardiovascular, immune, respiratory, gastrointestinal/hepatic and biliary, renal and urinary, neurological, musculoskeletal, mental, infectious, metabolic diseases, and malignancies 2. Diagnosed with or has a history of gastrointestinal diseases (irritable bowel syndrome, colitis, ulcerative colitis, abdominal diseases etc.), or has undergone gastrointestinal surgery 3. Individuals with severe lactose intolerance 4. History of bowel obstruction 5. Alcohol addiction or substance abuse 6. Hospitalized within the last 3 months of Visit 1 7. Has taken medication affecting body weight {anti-obesity drugs (appetite suppressants, fat absorption inhibitors, Glucagon-like peptide-1 (GLP-1) receptor agonists etc.), psychiatric drugs such as antidepressants and antipsychotics, diuretics, contraceptives, steroids, female hormones, thyroid hormones} within the last 3 months of Visit 1 8. Has taken immunosuppressive drugs or anti-inflammatory drugs within the last month (30 days) of Visit 1 9. Administered antibiotics or laxatives within the last 2 weeks of Visit 2 10. Has taken prokinetics (Serotonin type 4 (5-HT4) Agonist, D2 Antagonists, Cholinergic Agonists etc.), laxatives {fiber supplements (Psyllium, Methylcellulose etc.), stool softeners, osmotic laxatives (Sorbitol, Lactulose etc.), stimulant laxatives (Bisacodyl, Anthraquinone etc.)} 11. Pregnant, breastfeeding, or planning to become pregnant during the study period 12. Allergic to dairy products 13. Participated in another interventional clinical trial (including human trials) within the last 3 months of Visit 1, or planning to participate in another interventional clinical trial (including human trials) after the start of this study 14. Individuals deemed inappropriate for the study by the investigator
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Digestive discomfort are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul National University Bundang Hospital
Seongnam-si, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.